ZS $113.97 -1.2563%
MUNI $52.09 -0.1533%
HDT.L $72.75 -4.2763%
BDLL3.SA $11.40 0%
SST $2.97 -1.0833%
HBT $16.84 0.0594%
CEPE3.SA $128.00 0%
3988.HK $3.21 -1.8349%
VFAIX $38.09 -0.3401%
SEQUA.BR $3.05 -1.6129%
HYB $6.67 -0.299%
MAV $7.94 -0.9975%
IYR $83.54 -0.7249%
HHS $5.55 -4.8027%
LABD $13.91 4.6275%
CUBA $3.88 0.2584%
8050.HK $0.16 0%
RTO.L $645.60 0.3419%
SPE.L $615.00 0%
PHVS $8.33 4.9811%
0UC0.L $3.62 -1.0929%
SPNV $8.80 0%
MPAA $5.51 -0.6318%
UNIT $3.62 -1.4986%
AEIS $85.03 -0.6078%
VJPA.L $28.07 0.5734%
OPA $10.34 0%
GRN $34.53 -0.2268%
IPU.L $427.00 1.9093%
0HX7.L $6.39 -11.3194%
FIAC $10.47 -0.0954%
BORR $6.76 -2.5252%
CLNY $8.50 0%
JARE.L $1.10 0%
SIXH $31.63 0.1057%
DFIN $44.05 -0.5868%
CEW $17.48 -0.5407%
SNTG $2.46 -10.5455%
1709.HK $2.61 0.3846%
AREBW $0.02 2.8995%
CMBS $46.80 -0.5715%
2326.HK $0.01 -9.0909%
USI $24.18 0%
0052.HK $12.52 1.6234%
NRGV $1.95 -2.505%
3668.HK $28.25 -2.921%
AQB $0.52 -2.0716%
MKL $1 361.08 -0.9307%
GEX $65.86 0%
IBTL.L $314.58 0.3749%
0HYR.L $103.93 0%
PSR $84.63 -0.6577%
2138.HK $4.78 -2.6477%
1314.HK $0.24 0%
CLVRW $0.03 30.2682%
HCAPZ $25.15 0%
2166.HK $1.93 -0.5155%
CPLE6.SA $7.80 -0.8894%
WABC $37.27 -1.0356%
6899.HK $0.33 -7.1429%
PACWP $8.69 -2.6878%
GWGH $2.89 0%
ELDN $2.46 -11.1913%
WULF $1.53 -5.5864%
6122.HK $2.19 0%
0QKB.L $2 000.00 0.3981%
BSX $52.98 -0.7773%
IEAC.L $116.10 -0.1634%
ESOZ.L $97.60 -0.4082%
MLPI.L $4.99 -2.0629%
2192.HK $7.86 -1.3802%
JGGI.L $455.50 0.1099%
0395.HK $0.02 0%
GWAV $0.85 3.6585%
ALCLS.PA $1.63 -6.7922%
XBLC.L $143.26 -0.1568%
ASDV.L $41.48 0.4115%
SOL $3.77 -1.5535%
SRLN $41.06 0.0365%
SVM $3.45 0.1453%
CLM $7.75 -0.875%
NOACU $10.04 0%
O $61.64 -0.267%
MTA.PA $118.75 -0.143%
IIIIU $10.08 0%
IMAQ $10.62 -0.1881%
SML.NZ $1.44 0%
J15R.L $84.17 -1.38262%
CITEU $10.55 0%
TMHC $43.27 -1.5472%
NFTY $44.46 -0.0674%
CAMT $26.69 0.395%
LUXU.L $228.45 -0.3272%
ROG $155.20 -1.052%
FRTY $12.18 -1.0448%
TRD.L $153.00 -1.2903%
PTTRX $8.68 0.2309%
EVS.BR $21.90 -0.4545%
NU $5.83 -1.4382%
Eng
Логотип
Eng
Лого

BerGenBio ASA 0RU5.L

$1.93

+$0.01 (0.73%)
На 18:02, 12 мая 2023

Ключевые показатели

  • Marketcap

    442321.00000000

  • week52high

    16.98

  • week52low

    1.81

  • Revenue

  • P/E TTM

    0

  • Beta

    1.68435100

  • EPS

    -3.50400000

  • Last Dividend

    0.28500000

  • Next Earnings Date

    07 мая 2023 г. в 04:04

Описание компании

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек